Tiss'You
Financial Overview – 2025 Partial (September 30th)

During the first nine months of 2025, Tiss'You SRL continued its strong growth trajectory, delivering results that already surpass the full-year performance of 2024.
Revenues reached €3.83 million, up +20% compared to the full 2024, driven mainly by international markets.
EBITDA stood at €1.70 million, underscoring the company's capacity to scale profitably.

Cash & Equivalents more than doubled, ensuring strong liquidity to support expansion.

Growth Drivers

- International Expansion: Export sales now account for the majority of revenue, with strong growth in Europe, Middle East, and Asia.
- Operational Leverage: Revenue growth outpaces operating expenses, boosting margins.
- Innovation Pipeline: Continuous investments in R&D and product development, reinforcing Tiss'You's leadership in regenerative medicine.

Outlook for Full-Year 2025
Given the strong results achieved by September, the company is on track to close 2025 with record revenues and profitability.

Strategic priorities include:

- Further expansion into new international markets.
- Scaling up production capacity in the San Marino facility.
- Strengthening the product portfolio through R&D investments.
- Continuing to build shareholder value through sustainable, profitable growth.
-

With these achievements, Tiss'You is positioned to exceed 2024 results well ahead of schedule, consolidating its role as a fast-growing and financially sound company in the regenerative medicine sector.

Tiss'You SRL
Dr. Paolo Fattori, PhD
CEO

Tiss'You s.r.l. Strada di Paderna n°2, 47895 Domagnano - RSM
sito: www.tissyou.com - email: info@tissyou.com - tissyou@pec.it -
Cap. Soc. € 25.500,00 - COE SM28226